S&P 500   4,190.60 (-0.35%)
DOW   32,938.43 (-0.32%)
QQQ   348.62 (-0.39%)
AAPL   179.22 (+1.08%)
MSFT   330.77 (-0.13%)
META   263.77 (+0.48%)
GOOGL   123.30 (-0.30%)
AMZN   120.22 (-1.18%)
TSLA   199.96 (-0.60%)
NVDA   386.83 (-3.56%)
NIO   7.38 (-0.40%)
BABA   79.21 (+0.69%)
AMD   119.98 (-4.22%)
T   15.81 (+1.09%)
F   12.07 (-4.13%)
MU   68.58 (-4.34%)
CGC   0.81 (-4.73%)
GE   100.94 (-1.43%)
DIS   87.90 (+0.09%)
AMC   4.46 (-3.67%)
PFE   37.76 (+2.03%)
PYPL   61.82 (-0.37%)
NFLX   395.27 (+0.58%)
S&P 500   4,190.60 (-0.35%)
DOW   32,938.43 (-0.32%)
QQQ   348.62 (-0.39%)
AAPL   179.22 (+1.08%)
MSFT   330.77 (-0.13%)
META   263.77 (+0.48%)
GOOGL   123.30 (-0.30%)
AMZN   120.22 (-1.18%)
TSLA   199.96 (-0.60%)
NVDA   386.83 (-3.56%)
NIO   7.38 (-0.40%)
BABA   79.21 (+0.69%)
AMD   119.98 (-4.22%)
T   15.81 (+1.09%)
F   12.07 (-4.13%)
MU   68.58 (-4.34%)
CGC   0.81 (-4.73%)
GE   100.94 (-1.43%)
DIS   87.90 (+0.09%)
AMC   4.46 (-3.67%)
PFE   37.76 (+2.03%)
PYPL   61.82 (-0.37%)
NFLX   395.27 (+0.58%)
S&P 500   4,190.60 (-0.35%)
DOW   32,938.43 (-0.32%)
QQQ   348.62 (-0.39%)
AAPL   179.22 (+1.08%)
MSFT   330.77 (-0.13%)
META   263.77 (+0.48%)
GOOGL   123.30 (-0.30%)
AMZN   120.22 (-1.18%)
TSLA   199.96 (-0.60%)
NVDA   386.83 (-3.56%)
NIO   7.38 (-0.40%)
BABA   79.21 (+0.69%)
AMD   119.98 (-4.22%)
T   15.81 (+1.09%)
F   12.07 (-4.13%)
MU   68.58 (-4.34%)
CGC   0.81 (-4.73%)
GE   100.94 (-1.43%)
DIS   87.90 (+0.09%)
AMC   4.46 (-3.67%)
PFE   37.76 (+2.03%)
PYPL   61.82 (-0.37%)
NFLX   395.27 (+0.58%)
S&P 500   4,190.60 (-0.35%)
DOW   32,938.43 (-0.32%)
QQQ   348.62 (-0.39%)
AAPL   179.22 (+1.08%)
MSFT   330.77 (-0.13%)
META   263.77 (+0.48%)
GOOGL   123.30 (-0.30%)
AMZN   120.22 (-1.18%)
TSLA   199.96 (-0.60%)
NVDA   386.83 (-3.56%)
NIO   7.38 (-0.40%)
BABA   79.21 (+0.69%)
AMD   119.98 (-4.22%)
T   15.81 (+1.09%)
F   12.07 (-4.13%)
MU   68.58 (-4.34%)
CGC   0.81 (-4.73%)
GE   100.94 (-1.43%)
DIS   87.90 (+0.09%)
AMC   4.46 (-3.67%)
PFE   37.76 (+2.03%)
PYPL   61.82 (-0.37%)
NFLX   395.27 (+0.58%)

Catalent (CTLT) Stock Forecast, Price & News

$37.34
+0.92 (+2.53%)
(As of 02:10 PM ET)
Compare
Today's Range
$36.11
$37.35
50-Day Range
$31.86
$67.51
52-Week Range
$31.45
$115.33
Volume
856,367 shs
Average Volume
3.63 million shs
Market Capitalization
$6.72 billion
P/E Ratio
16.52
Dividend Yield
N/A
Price Target
$67.55

Catalent MarketRank™ Forecast

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
82.4% Upside
$67.55 Price Target
Short Interest
Healthy
3.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.36mentions of Catalent in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$105,903 Sold Last Quarter
Proj. Earnings Growth
91.84%
From $0.98 to $1.88 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.18 out of 5 stars

Medical Sector

14th out of 1,006 stocks

Pharmaceutical Preparations Industry

5th out of 492 stocks


CTLT stock logo

About Catalent (NYSE:CTLT) Stock

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory manag

Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Stock News Headlines

Catalent Inc CTLT Stock Quote
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Barclays Trims Catalent (NYSE:CTLT) Target Price to $35.00
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Catalent (NYSE:CTLT) Shares Gap Down After Analyst Downgrade
What To Know About JP Morgan's Downgrade of Catalent
Catalent (NYSE:CTLT) PT Lowered to $35.00 at Robert W. Baird
StockNews.com Begins Coverage on Catalent (NYSE:CTLT)
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Company Calendar

Last Earnings
11/01/2021
Today
5/31/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
19,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$67.55
High Stock Price Forecast
$145.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+85.6%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
11 Analysts

Profitability

Net Income
$503 million
Pretax Margin
10.60%

Debt

Sales & Book Value

Annual Sales
$4.83 billion
Cash Flow
$5.71 per share
Book Value
$26.76 per share

Miscellaneous

Free Float
179,045,000
Market Cap
$6.56 billion
Optionable
Optionable
Beta
1.17

Key Executives

  • Alessandro MaselliAlessandro Maselli
    President, Chief Executive Officer & Director
  • Ricky Hopson
    Chief Financial Officer
  • Kay SchmidtKay Schmidt
    Senior Vice President-Technical Operations
  • Lim Chin Wei
    Manager-Global Scientific Affairs
  • Julien Meissonnier
    Chief Scientific Officer & Vice President













CTLT Stock - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price forecast for 2023?

11 brokers have issued twelve-month price targets for Catalent's stock. Their CTLT share price forecasts range from $28.00 to $145.00. On average, they expect the company's share price to reach $67.55 in the next year. This suggests a possible upside of 85.6% from the stock's current price.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2023?

Catalent's stock was trading at $45.01 at the start of the year. Since then, CTLT stock has decreased by 19.1% and is now trading at $36.40.
View the best growth stocks for 2023 here
.

Are investors shorting Catalent?

Catalent saw a drop in short interest in April. As of April 15th, there was short interest totaling 5,850,000 shares, a drop of 8.6% from the March 31st total of 6,400,000 shares. Based on an average trading volume of 2,920,000 shares, the days-to-cover ratio is currently 2.0 days.
View Catalent's Short Interest
.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) issued its quarterly earnings data on Monday, November, 1st. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.06. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. Catalent had a trailing twelve-month return on equity of 11.40% and a net margin of 8.62%. During the same period in the previous year, the business posted $0.33 earnings per share.
Read the conference call transcript
.

What guidance has Catalent issued on next quarter's earnings?

Catalent updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.25 billion-$4.35 billion, compared to the consensus revenue estimate of $4.44 billion.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.95%), Artisan Partners Limited Partnership (4.30%), State Street Corp (4.00%), Veritas Asset Management LLP (3.82%), American Century Companies Inc. (2.44%) and Geode Capital Management LLC (2.07%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph.
View institutional ownership trends
.

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $36.40.

How much money does Catalent make?

Catalent (NYSE:CTLT) has a market capitalization of $6.56 billion and generates $4.83 billion in revenue each year. The company earns $503 million in net income (profit) each year or $2.26 on an earnings per share basis.

How many employees does Catalent have?

The company employs 19,000 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.

This page (NYSE:CTLT) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -